DOACs have bleeding risk comparable to warfarin

A new type of drug used to treat blood clots does not put patients at a higher bleeding risk than warfarin, researchers have found Recent trials have shown similar effectiveness and a reduced or similar risk of major bleeding complications for DOACs compared with warfarin, the authors of the new study say. However, clinical trials

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Assisted dying debate begins
Next World news wrapup: 19 October 2017